School of Medicine
Showing 1-10 of 10 Results
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Clinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
Daniel Alexander King
Postdoctoral Medical Fellow, Oncology
Bio Daniel Alexander King, MD, PhD (Oncology Fellow)
Originally from Long Island, NY, Dan trained at Cold Spring Harbor Laboratory, the University of Michigan (BS), Wayne State University (MD), the National Human Genome Research Institute (HHMI Research Scholars Program), Cambridge University (PhD), and Columbia University (Internal Medicine Residency). He enjoys mutation hunting in large-scale genomic data. He was most recently involved in an exome sequencing study of 12,000 children with rare disease and their parents, in which he developed new computational tools to identify large genetic aberrations. His mutational spectrum of interest includes uniparental disomy, copy number alterations, and mosaicism. He plans to explore research opportunities riding the intersection of new technology & genomics, such as single cell DNA & RNA sequencing, and circulating tumor DNA.
Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Kummar?s research interests focus on developing novel therapies for cancer. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. Her studies integrate genomics and laboratory correlates into early phase trials. She is interested in alternate trial designs to facilitate rational drug selection based on human data and help expedite drug development timelines. She has published numerous articles in medical journals and serves on a number of national and international scientific committees.
Pamela L. Kunz
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Bio Dr. Kunz specializes in the treatment of gastrointestinal malignancies with an expertise in the care of patients with neuroendocrine tumors (NETs). She has developed broad investigative programs in the field of neuroendocrine tumors (NETs), encompassing clinical trials, population sciences, and translational correlates. Stanford has a robust referral base for neuroendocrine tumors and has demonstrated successful accrual to clinical trials in this rare disease. She has been involved with the design, development and conduct of Phase I, II, and III clinical trials in this field. She holds a number of leadership positions in the field including Vice Chair of the Neuroendocrine Tumor Taskforce of the National Cancer institute and member of the NANETS Board of Directors. She also serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel and the NET Working Group of the Eastern Cooperative Oncology Group (ECOG) and is the founding Director of the Stanford Neuroendocrine Tumor Program, established in 2015.
Allison W. Kurian, M.D., M.Sc.
Associate Professor of Medicine (Oncology) and of Health Research and Policy at the Stanford University Medical Center
Current Research and Scholarly Interests I aim to improve the outcomes of women's cancers through clinically-oriented research on genetic risk assessment, risk-adapted screening and prevention.
Instructor, Medicine - Oncology
Current Research and Scholarly Interests Implementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.